Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

B E De Galan, Sophia Zoungas, J Chalmers, Craig Anderson, Carole Dufouil, Avinesh Pillai, M E Cooper, D E Grobbee, M Hackett, P Hamet, S R Heller, Liu Lisheng, Stephen MacMahon, Giuseppe Mancia, B Neal, C Y Pan, A Patel, N Poulter, Florence Travert, M Woodward

    Research output: Contribution to journalArticleResearchpeer-review

    197 Citations (Scopus)


    The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial
    Original languageEnglish
    Pages (from-to)2328 - 2336
    Number of pages9
    Issue number11
    Publication statusPublished - 2009

    Cite this